FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death

Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a short median survival despite multimodal therapy. FTY720, an immunosuppressive drug approved for the treatment of multiple sclerosis, promotes MCL cell death concurrent with down-modulation of phospho-Akt and cyclin D1 and subseque...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Alinari, Lapo, Mahoney, Emilia, Patton, John, Zhang, Xiaoli, Huynh, Lenguyen, Earl, Christian T., Mani, Rajeswaran, Mao, Yicheng, Yu, Bo, Quinion, Carl, Towns, William H., Chen, Ching-Shih, Goldenberg, David M., Blum, Kristie A., Byrd, John C., Muthusamy, Natarajan, Prætorius-Ibba, Mette, Baiocchi, Robert A.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2011
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3568700/
https://ncbi.nlm.nih.gov/pubmed/22042694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-06-363879
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars